Список проголосовавших за комментарий " On The Wires<ul><li>JA Solar Holdings (<strong>JASO</strong>) announced that China Export & Credit Insurance Corporation provided export buyer's credit insurance to export around 300 MW JA Solar modules for a PV project developed by the multinational energy company ENEL S.p.A. in Brazil. The total amount insured was US $145 million.</li><li>MediWound Ltd. (<strong>MDWD</strong>) announced that the European Medicines Agency has endorsed the extension of the Children Innovative Debridement Study (CIDS) population to include patients age one to 18. Based on the recommendation of the study's Data Safety Monitoring Board (DSMB), after blindly reviewing the accumulated CIDS data, and the EMA endorsement, MediWound will initiate the second stage of the study that allows inclusion of younger pediatric burn patients beginning at the minimum age of one instead of four years of age.</li><li>The European Commission has approved, under the EU Merger Regulation, the acquisition of Fyffes (<strong>FYFFF</strong>) of Ireland by Sumitomo of Japan. Fyffes is active in the production, procurement, distribution and marketing of fresh fruits and mushrooms. Fyffes also provides ripening services to third parties. Sumitomo is active in a wide range of sectors, including the production, procurement and distribution of vegetable and fresh fruits through its subsidiary Sumifru. The Commission concluded that the proposed acquisition would raise no competition concerns because the companies' activities do not overlap in the European Economic Area.</li><li>Veeva Systems (<strong>VEEV</strong>) announced Veeva Vault Submissions Publishing, a new cloud application that seamlessly incorporates publishing capabilities within Veeva Vault RIM to speed regulatory submission delivery. The addition of Vault Submissions Publishing unifies publishing capabilities and enterprise content management to streamline end-to-end submission development. Now life sciences companies can plan, review, publish, archive, and validate submissions within a single cloud platform.</li><li>Immunovaccine announced that the UHN's Princess Margaret Cancer Center will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck (<strong>MRK</strong>). </li><li>RADCOM (<strong>RDCM</strong>) announced that it has appointed Rami Amit, a telecom industry veteran, to its newly created Chief Technology Officer and Head of Product position to advance its first mover advantage in the growing market of NFV-ready service assurance. Rami will play a key role in shaping RADCOM's technology strategy and vision, as the company looks to provide Communication Service Providers with a cost effective, highly scalable, software only solution to assure their customer experience.</li></ul>"